Early Post-marketing Study of Eliquis (Apixaban)

Bristol-Myers Squibb (BMS)

Status: Withdrawn

Conditions: Non-valvular Atrial Fibrillation (NVAF)

Treatments: Drug: Apixaban

Study type: Observational

Funder types: Industry

Identifiers

NCT02153424

CV185-330

Details and patient eligibility

About

The primary objective of the study is to identify and describe any suspected (AEs) in all patients with NVAF treated with Apixaban, as a request of the National Center of Pharmacovigilance (CNFV) in Mexico.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• All patients with NVAF at the sentinel site for the CNFV in Mexico who received at least 1 dose of Apixaban to reduce the risk of stroke or systemic embolism during the specified 24-month study period

Exclusion Criteria:

• Subjects who received Apixaban as part of a clinical trial
• Subjects who received Apixaban for any indication other than local approval (ie, to reduce the risk of stroke and systemic embolism in patients with NVAF)

Trial design

0 participants in 1 patient group

NVAF patients in Mexico treated with Apixaban

Description:

All patients with NVAF at the sentinel site for the CNFV in Mexico who received at least 1 dose of Apixaban to reduce the risk of stroke or systemic embolism during the specified 24-month study period

Treatment:

Drug: Apixaban